A new study debunks the common assumption that high medical costs are a result of patients demanding more tests and treatments. Researchers analyzed more than 5000 patient-clinician visits and found that cancer patients rarely push for medical interventions.
A new study debunks the common assumption that high medical costs are a result of patients demanding more tests and treatments. Researchers analyzed more than 5000 patient-clinician visits and found that cancer patients rarely push for medical interventions.
The study, published in JAMA Oncology, found that just 8.7% of patient visits included a patient demanding or requesting additional tests and treatments. Clinicians complied with 83% of the requests they deemed clinically appropriate. For the 50 demands for clinically inappropriate tests or treatments, clinicians only complied with 7 of them, which is just 0.14% of the total 5000 encounters.
“We decided to look specifically at cancer patients’ demands because oncology is a setting where there are life-and-death stakes for patients, and the drugs and tests can get very expensive,” senior author Ezekiel Emanuel, MD, PhD, chair of the department of medical ethics and health policy at the Perelman School of Medicine at the University of Pennsylvania, said in a statement. “However, we found, contrary to expectations, that patient demands are low and cannot be a key driver of increasing healthcare costs.”
Half of the requests were for imaging studies, 13.6% for laboratory tests, such as tumor markers, and 5.2% were for genetic tests or chemosensitivity tests. The authors were surprised to learn that 15.5% of patients requested palliative care interventions such as pain medications or sleeping aids.
“In this age of unregulated consumer medical information on the Internet, it’s encouraging to see that this hasn’t translated to cancer patients requesting inappropriate—and often costly—tests and treatments,” lead author Keerthi Gogineni, MD, MSHP, said.
The 60 clinicians—34 oncologists, 11 oncology fellows, and 15 nurse practitioners and physician assistants—were from 3 Philadelphia hospitals: the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, and Pennsylvania Hospital.
Patients with lung/head and neck cancer and receiving active treatments were more likely to make demands or requests. The relationship with the clinician also had an affect; patients with worse relationships with their physicians were more likely to request or demand additional tests or treatment.
“Given the rarity of clinically inappropriate demands or requests, that few were high cost, and that few were complied with, they are unlikely to add significantly to health care costs,” the authors concluded in their paper.
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Age Alone Is No Barrier to Allo-HCT for AML, Data Indicate
April 17th 2024A new study is among the largest real-world analyses to date to assess trends over time and predictive factors for older patients with acute myeloid leukemia (AML) who received allogeneic hematopoietic cell transplantation (allo-HCT).
Read More
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More